Erytech is building an innovative platform to develop next generation of targeted delivery system based on red blood cell-derived extracellular vesicles (RBCEV). RBCEV are formed naturally during senescence and storage of mature RBCs. Due to their intrinsic properties (small size, natural targeting to immune cells, lack of nucleic acids, wide range of potential routes of administration, readily available sourcing of RBCs for their production), RBCEV are a potentially attractive drug delivery system.
ERYTECH’s proprietary ERYCEVTM platform leverages the proprietary ERYCAPS® technology and vesiculation to produce cargo loaded RBCEVs. A broad range of cargoes are possible, including small molecules, RNA, DNA, peptides/proteins and viruses. ERYCEVTM is believed to have potential therapeutic applications in oncology, genetic, inflammatory and infectious diseases.